 TEL AVIV, Israel, Jan. 20, 2021 PRNewswire -- BioLineRx Ltd. NASDAQ: BLRX TASE: BLRX, a late clinical-stage biopharmaceutical company focused on oncology, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and... 